Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates
BNT162b2 was associated with a lower incidence and severity of systemic reactions. In each of 13 groups of 15 participants, 12 participants received a vaccine and 3 received a placebo. The trial was conducted in the United States.
